AR, a key enzyme in the polyol pathway, targeting AR may ameliorate pulmonary artery hypertension, reduce the expression of hypoxia-inducible factors and vascular endothelial growth factors, alleviate inflammatory responses, and improve osmotic stress. Here, VEGFA is linked to pulmonary arterial hypertension.